Digest Network Come funziona
Network
/
Società
Tu
Non verificato

Tubulis

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

14 comunicati stampa

Guarda tutti i comunicati
27/01/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board
Fonte
Tubulis
Emittente
Business Wire
1.00
0
21/01/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Industria
Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications
Fonte
Tubulis
Emittente
Business Wire
1.00
0
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Mercato del lavoro
Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development
Fonte
Tubulis
Emittente
Business Wire
1.00
0
16/12/2025
Eventi
Sanità
Salute
Farmaceutica
Medicina - Varie
Oncologia
Tubulis to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Tubulis
Emittente
Business Wire
1.00
0
30/10/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Vetrine/Shopping
Medicina - Varie
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)
Fonte
Tubulis
Emittente
Business Wire
1.00
0
19/10/2025
Scienza
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
Eventi
Industria
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
Fonte
Tubulis
Emittente
Business Wire
1.00
0
15/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline
Fonte
Tubulis
Emittente
Business Wire
1.00
0
22/09/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Tubulis to Present First Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-Resistant Ovarian Cancer in Late-Breaking Oral Presentation at ESMO 2025
Fonte
Tubulis
Emittente
Business Wire
1.00
0
09/09/2025
Scienza
Legge/Diritto
Biotecnologia
Farmaceutica
Oncologia
Salute
Associazioni/Professionisti
Mercato del lavoro
Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer
Fonte
Tubulis
Emittente
Business Wire
1.00
0
06/02/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
Fonte
Tubulis
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0